Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Allakos Inc. ALLK

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.


Recent & Breaking News (NDAQ:ALLK)

Allakos Announces Upsizing and Pricing of Public Offering of Common Stock

GlobeNewswire August 6, 2019

Allakos Announces Proposed Public Offering of Common Stock

GlobeNewswire August 5, 2019

Allakos Reports Second Quarter 2019 Financial Results

GlobeNewswire August 5, 2019

Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)

GlobeNewswire August 5, 2019

Allakos Reports First Quarter 2019 Financial Results

GlobeNewswire May 8, 2019

Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis

GlobeNewswire May 7, 2019

Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights

GlobeNewswire March 14, 2019

Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis

GlobeNewswire February 19, 2019

Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts

GlobeNewswire February 11, 2019

Allakos to Host Investor Day on February 19 in New York City

GlobeNewswire February 4, 2019

Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

GlobeNewswire January 29, 2019

Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients

GlobeNewswire January 7, 2019

New Research Coverage Highlights TheStreet, EVO Payments, Odyssey Marine Exploration, Allakos, SORL Auto Parts, and SPAR Group — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire November 21, 2018

Allakos Announces Clinical Update and Third Quarter 2018 Financial Results

GlobeNewswire November 8, 2018

Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting

GlobeNewswire October 8, 2018

Allakos Announces Second Quarter 2018 Financial Results

GlobeNewswire August 29, 2018

Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire July 24, 2018

Allakos Announces Pricing of Initial Public Offering

GlobeNewswire July 19, 2018